Lapatinib - Generic Drug Details
✉ Email this page to a colleague
US Patents and Regulatory Information for lapatinib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Usa Inc | LAPATINIB DITOSYLATE | lapatinib ditosylate | TABLET;ORAL | 217968-001 | Aug 16, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Novartis | TYKERB | lapatinib ditosylate | TABLET;ORAL | 022059-001 | Mar 13, 2007 | AB | RX | Yes | Yes | 8,821,927 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |
| Natco Pharma Ltd | LAPATINIB DITOSYLATE | lapatinib ditosylate | TABLET;ORAL | 203007-001 | Sep 29, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
